A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs WVE 120101 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; First in man
- Acronyms PRECISION-HD1
- Sponsors WaVe life Sciences
- 08 Aug 2017 According to a WaVe life Sciences media release, completion of this trial is anticipated for 2H 2019.
- 25 Jul 2017 New source identified and integrated (ClinicalTrials.gov; NCT03225833)
- 17 Jul 2017 Status changed from planning to recruiting, according to a Wave Life Sciences media release.